News | May 14, 2022
CCMB develops India’s first mRNA vaccine technology
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
This is a shot in the arm for the vaccine manufacturers
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
